Do analysts prefer ACTU or ETHZ?

Actuate Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Actuate Therapeutics is more favorable than Flag Ship Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACTU or ETHZ more profitable?

Flag Ship Acquisition's return on equity of -185.71% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Flag Ship Acquisition N/A -185.71% -83.12%

Which has preferable earnings & valuation, ACTU or LIXT?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A

Is ACTU or LIXT more profitable?

Lixte Biotechnology's return on equity of -134.91% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Lixte Biotechnology N/A -134.91% -95.61%

Is RANI or ACTU more profitable?

Rani Therapeutics' return on equity of -206.46% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Actuate Therapeutics N/A -430.93% -180.86%

Which has stronger earnings & valuation, PLYX or ACTU?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A -$0.05 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is PLYX or ACTU more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Actuate Therapeutics N/A -430.93% -180.86%

Which has better valuation & earnings, BDTX or ACTU?

Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics N/A N/A $22.37M -$0.77 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is BDTX or ACTU more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Actuate Therapeutics N/A -430.93% -180.86%

Actuate Therapeutics (ACTU) Competitors

$1.18 -0.08 (-6.35%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.20 +0.02 (+1.27%)

As of 07/24/2026 07:34 PM Eastern

Compare

ACTU vs. ETHZ, LIXT, RANI, PLYX, and BDTX

Should you buy Actuate Therapeutics stock or one of its competitors? MarketBeat compares Actuate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actuate Therapeutics include Flag Ship Acquisition (ETHZ), Lixte Biotechnology (LIXT), Rani Therapeutics (RANI), Polaryx Therapeutics (PLYX), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Actuate Therapeutics compare to Flag Ship Acquisition?

Actuate Therapeutics (NASDAQ:ACTU) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Actuate Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Actuate Therapeutics is more favorable than Flag Ship Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Flag Ship Acquisition's return on equity of -185.71% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Flag Ship Acquisition	N/A	-185.71%	-83.12%

In the previous week, Actuate Therapeutics had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 1 mentions for Actuate Therapeutics and 0 mentions for Flag Ship Acquisition. Actuate Therapeutics' average media sentiment score of 1.89 beat Flag Ship Acquisition's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Very Positive
Flag Ship Acquisition	Neutral

Flag Ship Acquisition has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Flag Ship Acquisition	$4.11M	26.50	-$6.17M	-$159.65	N/A

4.1% of Flag Ship Acquisition shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Actuate Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Summary

Actuate Therapeutics and Flag Ship Acquisition tied by winning 7 of the 14 factors compared between the two stocks.

How does Actuate Therapeutics compare to Lixte Biotechnology?

Actuate Therapeutics (NASDAQ:ACTU) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Actuate Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

5.1% of Lixte Biotechnology shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Actuate Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Lixte Biotechnology's return on equity of -134.91% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Lixte Biotechnology	N/A	-134.91%	-95.61%

In the previous week, Actuate Therapeutics had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 1 mentions for Actuate Therapeutics and 0 mentions for Lixte Biotechnology. Actuate Therapeutics' average media sentiment score of 1.89 beat Lixte Biotechnology's score of 0.84 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Very Positive
Lixte Biotechnology	Positive

Summary

Actuate Therapeutics beats Lixte Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

In the previous week, Rani Therapeutics had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Rani Therapeutics and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.89 beat Rani Therapeutics' score of 0.93 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Rani Therapeutics	Positive
Actuate Therapeutics	Very Positive

Rani Therapeutics' return on equity of -206.46% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Actuate Therapeutics	N/A	-430.93%	-180.86%

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Actuate Therapeutics has lower revenue, but higher earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$3.17M	33.26	-$29.67M	-$0.41	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Rani Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Rani Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 928.32%. Actuate Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 1,383.05%. Given Actuate Therapeutics' higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Rani Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Rani Therapeutics beats Actuate Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.89 beat Polaryx Therapeutics' score of 0.31 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Actuate Therapeutics	Very Positive

Polaryx Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Actuate Therapeutics	N/A	-430.93%	-180.86%

Polaryx Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Actuate Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Polaryx Therapeutics and Actuate Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Actuate Therapeutics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.89 beat Black Diamond Therapeutics' score of 1.46 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
Actuate Therapeutics	Very Positive

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Black Diamond Therapeutics currently has a consensus price target of $9.83, suggesting a potential upside of 458.71%. Actuate Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 1,383.05%. Given Actuate Therapeutics' higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.77	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Black Diamond Therapeutics' return on equity of -30.18% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Black Diamond Therapeutics has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Summary

Black Diamond Therapeutics beats Actuate Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.15M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.22	21.29	27.11	23.64
Price / Sales	N/A	170.12	517.09	89.57
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	3.47	7.88	10.28	6.07
Net Income	-$22.23M	$23.86M	$3.60B	$331.99M
7 Day Performance	-18.06%	-3.82%	-1.27%	-0.63%
1 Month Performance	-39.80%	-2.61%	-0.37%	-2.00%
1 Year Performance	-83.75%	32.79%	18.30%	13.62%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	2.6342 of 5 stars	$1.18 -6.3%	$17.50 +1,383.1%	-83.1%	$30.15M	N/A	N/A	10	Positive News Gap Down
ETHZ Flag Ship Acquisition	N/A	$6.13 +1.2%	N/A	N/A	$116.54M	$4.11M	N/A	7
LIXT Lixte Biotechnology	0.2761 of 5 stars	$7.51 +4.2%	N/A	+75.1%	$112.80M	N/A	N/A	4	Gap Up
RANI Rani Therapeutics	1.8862 of 5 stars	$0.87 +25.5%	$8.75 +909.2%	+69.7%	$108.03M	$3.17M	N/A	110	Gap Down High Trading Volume
PLYX Polaryx Therapeutics	3.352 of 5 stars	$2.29 -1.3%	$8.50 +271.0%	N/A	$107.75M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ETHZ, LIXT, RANI, PLYX, and BDTX

How does Actuate Therapeutics compare to Flag Ship Acquisition?

Summary

How does Actuate Therapeutics compare to Lixte Biotechnology?

Summary

How does Actuate Therapeutics compare to Rani Therapeutics?

Summary

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Summary

How does Actuate Therapeutics compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ETHZ, LIXT, RANI, PLYX, and BDTX

How does Actuate Therapeutics compare to Flag Ship Acquisition?

Do analysts prefer ACTU or ETHZ?

Is ACTU or ETHZ more profitable?

Does the media prefer ACTU or ETHZ?

Which has preferable valuation and earnings, ACTU or ETHZ?

Do institutionals and insiders have more ownership in ACTU or ETHZ?

Which has more risk & volatility, ACTU or ETHZ?

Summary

How does Actuate Therapeutics compare to Lixte Biotechnology?

Do analysts prefer ACTU or LIXT?

Which has preferable earnings & valuation, ACTU or LIXT?

Do institutionals & insiders believe in ACTU or LIXT?

Which has more volatility & risk, ACTU or LIXT?

Is ACTU or LIXT more profitable?

Does the media refer more to ACTU or LIXT?

Summary

How does Actuate Therapeutics compare to Rani Therapeutics?

Does the media prefer RANI or ACTU?

Is RANI or ACTU more profitable?

Do insiders and institutionals hold more shares of RANI or ACTU?

Which has higher valuation and earnings, RANI or ACTU?

Which has more volatility and risk, RANI or ACTU?

Do analysts recommend RANI or ACTU?

Summary

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Which has stronger earnings & valuation, PLYX or ACTU?

Does the media refer more to PLYX or ACTU?

Is PLYX or ACTU more profitable?

Do analysts rate PLYX or ACTU?

Summary

How does Actuate Therapeutics compare to Black Diamond Therapeutics?

Does the media favor BDTX or ACTU?

Do insiders and institutionals hold more shares of BDTX or ACTU?

Do analysts rate BDTX or ACTU?

Which has better valuation & earnings, BDTX or ACTU?

Is BDTX or ACTU more profitable?

Which has more risk and volatility, BDTX or ACTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools